TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with probable or definite ALS by El Escorial Criteria between ages 20-85 will be included for evaluation. They must have progression of disease over the preceding 6 months and duration of disease less then 5 years.~Exclusion Criteria:~* Patients who do not meet clinical criteria of the diagnosis including those with pure upper motor neuron syndromes (PLS) or pure lower motor syndromes (SMA, Multifocal conduction block, motor neuropathies).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ALS (Type: None): Subjects having either definite or probable ALS by El Escorial Criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient is 18 years and older.~2. Patient is documented to be HBsAg positive for \> 6 months and HBV DNA positive.~3. Patient is HBeAg positive or negative.~4. Patient has ALT levels ≥ 80 IU/L~5. Patient who is able to give written informed consent prior to study start and to comply with the study requirements.~Exclusion Criteria:~1. Patient is currently receiving antiviral, immunomodulatory, cytotoxic or corticosteroid therapy.~2. Patients previously treated with interferon within the previous 3 months.~3. Patients previously treated with clevudine, lamivudine, adefovir, entecavir, telbivudine or any other investigational nucleoside for HBV infection.~4. Patient is coinfected with HCV, HDV or HIV.~5. Patient is pregnant or breast-feeding.~6. Patient has a clinically relevant history of abuse of alcohol or drugs.~7. Patient has a significant immunocompromised, gastrointestinal, renal, hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone, neurological, cardiac, oncologic(except HCC)or allergic disease or medical illness that in the investigator's opinion might interfere with therapy.~8. Patient has creatinine clearance less than 60mL/min as estimated by the following formula: (140-age in years) (body weight \[kg\])/(72) (serum creatinine \[mg/dL\]) \[Note: multiply estimates by 0.85 for women\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine and Ketamine in Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years old and less than 75 years years old~* Horizontal abdominal incision~Exclusion Criteria:~* Emergency or urgent procedure~* Preexisting chronic pain (at any site) requiring treatment~* Contraindication to any study medication (ketamine or lidocaine)~* History of significant Axis I psychiatric disease (major depressive disorder, bipolar disorder, schizophrenia, etc.)~* Significant hepatic (ALT or AST \> 2 times normal) or renal (serum creatinine \> 2 mg/dl) impairment~* Seizure disorder requiring medication within past 2 years~* Planned spinal or epidural anesthesia or analgesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
- Placebo (Type: PLACEBO_COMPARATOR): A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
- Ketamine (Type: ACTIVE_COMPARATOR): Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
- ketamine + Lidocaine (Type: ACTIVE_COMPARATOR): both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed medulloblastoma~2. Standard-risk disease~3. No residual tumor greater than 1.5 cm\^2 after resection by postoperative MRI~   * No tumor in the spinal or cerebral subarachnoid space by MRI~  * No tumor in the subarachnoid space by Cerebrospinal fluid (CSF)~  * No failure to perform staging studies (spine MRI and CSF cytology) preoperatively or postoperatively~4. Must begin radiotherapy on study within 28 days after surgery~Exclusion Criteria:~1. Prior radiotherapy and anti-tumor chemotherapy other than corticosteroids are not allowed.~2. Pregnant females will not be eligible~3. Patients must begin radiotherapy on protocol within 28 days of completion of surgery. Exceptions need to be approved by the Principal Investigator.~4. Patients with the following will not be eligible:~   * \> 1.5cm3 residual tumor following resection as indicated by post-operative MRI.~  * tumor in spinal or cerebral subarachnoid space either by MRI of brain and spine~  * tumor in subarachnoid space by CSF cytology~  * failure to perform staging studies (spine MRI, CSF cytology) either pre- or post- operatively

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Study Treatment (Type: EXPERIMENTAL): All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatment is completed, all subjects will begin 9 cycles (each cycle lasts 6 weeks) of maintenance chemotherapy which will be given as 2 different drug combinations, Regimen A (Lomustine, Vincristine, and Cisplatin) and Regimen B (Cyclophosphamide, given with Mesna, and Etoposide \[IV and oral\]) which will be given in the following order: AABAABAAB (total of 54 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent,~* Age ≥ 18 years,~* Patients with well differenciated digestive neuroendocrine tumors and liver metastases, for whom a complete surgical resection of liver metastases and of the primary tumor was performed, in 1 or 2 times,~* Immunohistochemical confirmation of neuroendocrine tumors with WHO 2010 grading specification and Ki67 determined of the surgical specimen,~* ECOG Performance Status (PS) 0-1,~* Adequate hematological status: Platelets \>100000/mm3, Hemoglobin \>10g/dL,~* Adequate Clearance Creatinine \>60 mL/min,~* Adequate liver function: Total Serum Bilirubin \<1.5x upper limit of normal (ULN), transaminases \<3 x ULN,~* Grade of In111-Pentetreotide uptake ≥ 2 (scored according to the Krenning et al scale.: more intense than physiological liver uptake),~* Treatment started within 14 weeks after surgical resection,~* Men and women are required to use adequate birth control measures during the course of the study and for a period of 12 months after the last administration of study drug. Female patients with childbearing potential must have a negative serum pregnant test (β-HCG) within 7 days before starting study treatment,~* Life expectancy \>6 months~* Registration with the National Health Care System (CMU included for France)~Exclusion Criteria:~* History of previous or second cancer or progressive cancer occurring within 5 years prior to inclusion, except for basal cell or squamous cell carcinoma,~* Patients with known sensibility or hypersensibility to In111- Pentetreotide or any component of the treatment drug,~* Pregnant or breast-feeding women without adequate birth control measures,~* Patient with known medical history of psychological or psychiatric disorders that may affect patient participation in study due to lack of cooperation or loss of autonomy preventing hospitalization and initiation of study treatment (in good radiation protection conditions),~* Treatment with any investigational drug within 28 days prior to study entry,~* Patient protected by law (tutelage or guardianship).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- metabolic radiotherapy (Type: EXPERIMENTAL): In111-Pentetréotide at 12, 18 and 24 weeks after surgery,
- No metabolic radiotherapy - simple monitoring (Type: ACTIVE_COMPARATOR): No metabolic radiotherapy - simple monitoring without theraoy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* symptomatic NYHA II or III chronic heart failure~* left ventricular systolic dysfunction~* moderate or severe chronic obstructive pulmonary disease~* with or without significant reversibility~Exclusion Criteria:~* beta-blocker contraindications~* non-dihydropyridine (diltiazem / verapamil) calcium channel blockers~* recent coronary percutaneous intervention or coronary artery bypass graft surgery~* haemodynamically significant valvular disease or hypertrophic cardiomyopathy.~* active myocarditis or pericarditis.~* recent cerebrovascular accident or transient ischaemic attack~* serious concurrent systemic disease, such as malignancy, resulting in likely reduced life expectancy~* pregnancy, childbearing potential with inadequate contraception, breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bisoprolol
- 2 (Type: PLACEBO_COMPARATOR): Identical appearance matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects of age ≥ 18 years and ≤ 85 years,~* The delay between OHCA and basic life support (no flow period) is ≤ 5 minutes,~* First recorded ECG exhibits a shockable rhythm (ventricular tachycardia/ventricular fibrillation).~Exclusion Criteria:~* The patient is still receiving cardiac massage at the time of admission in the cath-lab,~* There is an obvious extra cardiac cause to the cardiac arrest (suicide, drowning, hanging, trauma etc.),~* The patient has prior coronary artery bypass grafting,~* The patient has incessant ventricular tachycardia/fibrillation,~* The patient has at least one acute or chronic coronary occlusion of an epicardial coronary artery ≥2.0mm of diameter on conventional angiography, The coronary artery anatomy does not allow realization of three vessels OCT according to the interventional cardiologist (severe tortuosity, severe calcifications etc.),~* The patient is in cardiogenic shock or with a left ventricular assistance device,~* The post ROSC ECG (12 leads) exhibits ST segment elevation (defined as a ≥1mm ST segment elevation in two or more contiguous standard leads or as a ≥2mm ST segment elevation in two or more precordial leads),~* The post ROSC ECG (12 leads) exhibits new left bundle block branch (LBBB).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Schizophrenia according to DSM IV~* Selected and treated in respect of the SPC (20 mg Serdolect max. and population at risk will be excluded)~Exclusion Criteria:~* DSM IV Axis I disorders other than schizophrenia: Substance-dependence (excepting nicotine-dependence and substance-abuse), recent (2 months) DSM IV diagnosis according to DIA-X of a major affective, anxiety disorder, eating-disorder.~* DSM IV Axis II disorders: Lifetime DSM IV diagnosis of personality disorder.~* ECG: QTc-interval \>450 msec.~* Systolic blood pressure \<100 mmHg~* Bradycardia (Hf \< 50/Min) und Arrhythmias~* Hypokalemia or Hypomagnesemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Schizophrenic patients treated with sertindole
- 2 (Type: ACTIVE_COMPARATOR): Schizophrenic patients treated with risperidone
- 3 (Type: NO_INTERVENTION): Healthy controls without any treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants 12 to 17 years (inclusive) of age at the time of informed consent~* Have a diagnosis of episodic migraine with or without aura according to International Classification of Headache Disorders-Third edition, beta version (ICHD-IIIB, 1.2.1 or 1.1) criteria, for at least 1 year prior to the screening/enrollment visit~* Experienced migraine attacks of moderate-to-severe intensity and typically lasting ≥ 3 hours untreated, occurring at a frequency of ≥ 2 to ≤ 14 attacks per month for the past 6 months prior to the screening/enrollment visit~* Participant's parent or legal guardian must be willing to sign a copy of the informed consent form as well as documentation for Written Authorization for Use and Release of Health and Research Study Information, after the nature and risks of study participation have been fully explained. Participants must be willing to provide informed assent.~Exclusion Criteria:~* Participants with ≥ 15 headache days per month in total (migraine, probable migraine, or tension-type)~* Participants with the following headache types: retinal (ICHD-IIIB, 1.2.4), with brainstem aura (ICHD-IIIB, 1.2.2), hemiplegic (ICHD-IIIB, 1.2.3), status migrainosus (ICHD-IIIB, 1.4.1), other forms of complicated migraine, or secondary headaches~* Participants who have not responded to an adequate dose and appropriate duration of treatment with 2 or more triptans~* Participants with known nasal obstruction, current uncontrolled nasopharyngeal illness, or known velum insufficiency (i.e., a cleft palate and/or structural abnormalities in the soft palate and nasopharynx) that may interfere with the proper use of study medication~* Participants whose conditions in the investigator's opinion may put the participant at significant safety risk or confound the study results. This includes participants who in the investigator's opinion should not be enrolled in the study due to the risks described in the Warnings and Precautions or Contraindications sections of the ONZETRA Xsail Prescribing Information.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Sumatriptan nasal powder (Type: EXPERIMENTAL): Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Use of the Neotech RAM Nasal Cannula for CPAP and Bi-PAP Application in Infants 28-42 Weeks Gestation in a Neonatal Intensive Care Unit (NICU)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion:~* Infants with birth weight \< 1500 grams AND/OR \<32 weeks gestational age~* Infants between 34-42 weeks gestational age and exclusive breastfeeding with no risk of nasal septal erosion OR Infants between 28-42 weeks gestational age at risk of nasal septal erosion~Exclusion:~* Infants with major congenital and upper airway anomalies~* Infants requiring ETT (endotracheal tube) mechanical ventilation~* Infants receiving no respiratory support

- Gender: ALL
- Minimum Age: 28 Weeks
- Maximum Age: 42 Weeks
- Healthy Volunteers: f

Study Arms:
- RAM Cannula (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotics on Recurrent Urinary Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women over 18 years of age.~* Women who have had at least one episode of UTI in the past 2 months~* Women with a well-documented history of recurrent UTIs: ≥2 infections in the past 6 months or ≥3 in the past 12 months.~* Women who have been treated with an antibiotic regimen for each episde of UTI~* Recurrence due to reinfection, not relapse: multiple infections should be spaced by a minimum of 2 weeks or in case of a shorter time, with negative urine culture between them~* Women who use contraception to prevent pregnancy and who do not plan a pregnancy during the study period~Exclusion Criteria:~* Pregnant or breastfeeding women~* Underlying chronic disease: diabetes mellitus, kidney failure, cancer, spinal cord injury, polycystic ovary~* Women wih catheters in the urethra~* Women who consume probiotics or foods, beverages or supplements containing extracts or parts of the genus Vaccinum sp, including other forms of V. macrocarpon (blueberry), V. myrtillus (European blueberry), V. angustifolium (wild or low buch blueberry), V. corymbosum (tall bch blueberry) or V. vitis-ideae (mountain blueberry) during the 2 weels prior to recruitment.~* High consumption of fruits rich in phenolic compounds, with special reference, to berries~* Women allergic to red fruits~* BMI ≥ 40 Kg/m2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): Probiotic formulation comprising Lactobacillus plantarum CECT8675 and CECT8677 in combination with cranberry, and vitamine C in a capsule format. Probiotic strains have Qualified Presumption of Safety (QPS) sttus by European Food Safety Authority.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo composed of maltodextrin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Asymptomatic Leishmania Infection in HIV Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* without a history of VL in the last 5 years~* stable residents of a VL-endemic area~* willing to participate and giving free informed consent~Exclusion Criteria:~* younger than 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Insecticidal School Uniforms for Dengue Prevention in Thailand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pupils in participating schools~Exclusion Criteria:~* skin sensitivity, exema

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- normal school uniforms (Type: PLACEBO_COMPARATOR): washing only
- insecticide-treated school uniforms (Type: EXPERIMENTAL): washing and insecticide treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy